Israele -
ebraico -
Ministry of Health
מבטרה 10 מגמל תוך ורידי
roche pharmaceuticals (israel) ltd - rituximab - תרכיז להכנת תמיסה לאינפוזיה - rituximab 10 mg/ml - rituximab - rituximab - mabthera is indicated for the following indications: * non-hodgkin’s lymphoma (nhl)mabthera is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, b-cell non-hodgkin’s lymphoma.mabthera is indicated for the treatment of previously untreated patients with low-grade or follicular lymphoma in combination with chemotherapy mabthera is indicated for the treatment of patients with cd20 positive diffuse large b-cell non-hodgkin's lymphoma in combination with chop chemotherapy. mabthera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. * chronic lymphocytic leukaemia (cll)mabthera in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including mabthera or patients refractory to previous mabthera plu
Israele -
ebraico -
Ministry of Health
מפקט
takeda israel ltd - mifamurtide - powder for suspension for infusion - mifamurtide 4 mg/vial - mifamurtide - mifamurtide - mepact is indicated in children, adolescents and young adults for the treatment of high grade resectable non metastatic osteosarcoma after macroscopically complete surgical resection. it is used in combination with post operative multi-agent chemotherapy. safety and efficacy have been assessed in studies of patients 2 to 30 years of age at initial diagnosis.
Israele -
ebraico -
Ministry of Health
טרנדייט טבליות 100 מג
padagis israel agencies ltd, israel - labetalol hydrochloride - טבליה - labetalol hydrochloride 100 mg - labetalol - labetalol - treatment of all grades of hypertension (mild, moderate and severe) when oral antihypertensive therapy is desirable.
Israele -
ebraico -
Ministry of Health
agili-c
cartiheal (2009) ltd. - רופא - agili-c implant is a bi-phasic, porous resorbable tissue regeneration scaffold for the treatment of focal articular cartilage and/or osteochondral defects. it is indicated for cartilage and/or bone repair. the implant serves as a scaffold for cellular and matrix ingrowth. the agili-c implant is expected to biodegrade within 6 – 12 months.
Israele -
ebraico -
Ministry of Health
zap-it!
ביופלן בע"מ - כלל האוכלוסיה - מכשיר המשמש להקלה לאחר עקיצות יתושים
Israele -
ebraico -
Ministry of Health
טיימלס-קרם ממצק לאיזור העיניים והשפתיים
אביב קוסמטיקס בעמ - שיפור מראה העור